疾病分类的精细度影响晚期系统性肥大细胞增多症的生存预测:单中心329例信息性病例研究
该单中心研究纳入329例晚期系统性肥大细胞增多症(SM-Adv)患者,比较WHO与国际共识分类(ICC)对生存预测的影响。多变量分析显示,ICC分型较WHO分型对生存预测更准确,且Mayo联盟风险因素具有独立预后贡献。
要点
- ICC分型较WHO分型对SM-Adv生存预测更准确。
- MCL-未成熟型生存显著差于MCL-成熟型(HR 15)。
- SM-AMN较ASM预后不同(HR 1.7),而SM-ALN与ASM无显著差异(P=0.37)。
核心结论
- ICC分型系统对SM-Adv具有独立预后贡献,Mayo联盟生存风险因素亦独立于分型系统。
研究设计与样本
- 单中心研究纳入329例SM-Adv患者,中位年龄65岁(范围18-88),男性58%。
主要发现
- WHO亚型:SM-AHN 212例(64%)、ASM 99例(30%)、MCL 18例(6%)。
- ICC亚型:SM-AMN 190例(64%)、ASM 99例(33%)、MCL 9例(3%)。
- MCL-未成熟型生存显著差于MCL-成熟型(HR 15,P<0.01)。
- ICC分型下MCL与SM-AHN/AMN预后区分 confirmed(HR 9.3,P<0.01),WHO分型下无显著差异(P=0.99)。
- MCL-成熟型与SM-AMN生存相似(P=0.18);SM-AMN较ASM预后不同(HR 1.7,P<0.01),SM-ALN与ASM无显著差异(P=0.37)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The World Health Organization (WHO) classification system categorizes advanced systemic mastocytosis (SM-Adv) into aggressive SM (ASM), mast cell leukemia (MCL), and SM with associated hematological neoplasm (SM-AHN). By contrast, the International Consensus Classification (ICC) requires "immature" MC cytomorphology for the diagnosis of MCL and limits SM-AHN to myeloid neoplasms (SM-AMN). The current study includes 329 patients with SM-Adv (median age 65 years, range 18-88; males 58%): WHO subcategories SM-AHN (N = 212; 64%), ASM (N = 99; 30%), and MCL (N = 18; 6%); ICC subcategories SM-AMN (N = 190; 64%), ASM (N = 99; 33%), and MCL (N = 9; 3%); WHO-defined MCL with "mature" MC cytomorphology and SM-AHN associated with lymphoid neoplasms were operationally labeled as "MCL-mature" (N = 9) and SM-ALN (N = 22), respectively, and distinguished from ICC-defined MCL and SM-AMN. Multivariable analysis that included the Mayo alliance risk factors for survival in SM (age >60 years, anemia, thrombocytopenia, increased alkaline phosphatase) revealed more accurate survival prediction with the ICC versus WHO classification order: (i) survival was significantly worse with MCL-immature versus MCL-mature (hazard ratio [HR] 15; p < .01), (ii) prognostic distinction between MCL and SM-AHN/AMN was confirmed in the context of ICC (HR 9.3; p < .01) but not WHO classification order (p = .99), (iii) survival was similar between MCL-mature and SM-AMN (p = .18), and (iv) SM-AMN (HR 1.7; p < .01) but not SM-ALN (p = .37) was prognostically distinct from ASM. The current study provides evidence for the independent prognostic contribution of both the ICC system for SM-Adv and the Mayo alliance risk factors for survival in SM.
引用
- Tefferi A, Abdelmagid M, Al-Kali A, et al. Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative cases. Am J Hematol. 2023. PMID: 37772442. doi:10.1002/ajh.27113
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。